XINJIANG BAI HUA CUN PHARMA TECH CO.,LTD Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd Stock
Equities
600721
CNE000000KQ1
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.7 CNY | +3.83% |
|
+11.11% | -26.36% |
| Sales 2022 | 350M 48.29M | Sales 2023 | 369M 50.96M | Capitalization | 2.95B 407M |
|---|---|---|---|---|---|
| Net income 2022 | -34M -4.69M | Net income 2023 | 13M 1.79M | EV / Sales 2022 | 6.22 x |
| Net cash position 2022 | 133M 18.41M | Net cash position 2023 | 200M 27.67M | EV / Sales 2023 | 7.44 x |
| P/E ratio 2022 |
-66.4
x | P/E ratio 2023 |
226
x | Employees | 731 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 55.22% |
More Fundamentals
* Assessed data
More news
| 1 day | +3.83% | ||
| 1 week | +11.11% | ||
| Current month | -8.65% | ||
| 1 month | -9.38% | ||
| 3 months | -16.54% | ||
| 6 months | -29.80% | ||
| Current year | -26.36% |
1 week
5.00
5.85
1 month
4.866.59
Current year
4.318.09
1 year
4.3111.21
3 years
3.4811.21
5 years
2.8011.21
10 years
2.8023.74
| Managers | Title | Age | Since |
|---|---|---|---|
Hui Huang
CEO | Chief Executive Officer | 40 | 20-12-23 |
Zi Yun Cai
DFI | Director of Finance/CFO | 51 | 17-11-23 |
Yan Xia
BRD | Director/Board Member | 44 | 21-09-16 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jing Song Wang
BRD | Director/Board Member | 60 | 21-09-16 |
Da Ming Li
BRD | Director/Board Member | 57 | 18-08-27 |
Li Gu
BRD | Director/Board Member | 55 | Dec. 20 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 5.7 | +3.83% | 14,556,600 |
| 24-04-25 | 5.49 | +3.39% | 12,937,600 |
| 24-04-24 | 5.31 | +1.92% | 5,873,483 |
| 24-04-23 | 5.21 | +3.17% | 6,183,500 |
| 24-04-22 | 5.05 | -1.56% | 5,140,159 |
End-of-day quote Shanghai S.E., April 25, 2024
More quotes
Xinjiang Bai Hua Cun Pharma Tech Co Ltd is a China-based company principally engaged in pharmaceutical services. The Company's main business is the research and development, registration and application of small molecule chemicals and the development of peptide drugs. The Company is engaged in the early discovery and screening of new drugs, drug clinical trials, biological sample analysis, medicine testing services, active pharmaceutical ingredient (API) and intermediate supply. The Company is also engaged in leasing and property services. The Company mainly conducts business within the domestic market.
Calendar
2024-08-21
- Q2 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -26.36% | 289M | |
| -2.31% | 103B | |
| +0.56% | 95.71B | |
| +1.69% | 22.02B | |
| -17.37% | 20.9B | |
| -9.30% | 17.85B | |
| -41.01% | 16.21B | |
| -14.85% | 15.52B | |
| +3.21% | 13.86B | |
| +33.54% | 12.04B |
- Stock Market
- Equities
- 600721 Stock
